C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: Novel muscarinic receptor antagonists

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2216-2226

  Kim, Myoung Goo ^a   Bodor, Erik T ^b   Wang, Chen ^a   Harden, T Kendall ^b   Kohn, Harold ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHOXYCARBONYL 4 HYDROXY 1 AZABICYCLO[3.3.1]NON 3 ENE; 8 BENZYLOXYMETHYL 3 ETHOXYCARBONYL 4 HYDROXY 1 AZABICYCLO[3.3.1]NON 3 ENE; 8 DIMETHYLAMINOMETHYL 3 ETHOXYCARBONYL 4 HYDORXY 1 AZABICYCLO[3.3.1]NON 3 ENE; ACRYLIC ACID ETHYL ESTER; AMMONIUM FORMATE; MUSCARINIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; CHROMATOGRAPHY; CYCLIZATION; DECARBOXYLATION; DIASTEREOISOMER; DIECKMANN REACTION; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LIGAND BINDING; PHARMACOPHORE;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; INOSITOL PHOSPHATES; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANES; MUSCARINIC ANTAGONISTS; RADIOLIGAND ASSAY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037573236     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020572p     Document Type: Article

References (41)

1. (a) Brown, J. H.; Taylor, P. In The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Eds.; McGraw-Hill: New York, 1996; Chapter 7, pp 141-160.
2. (b) Cannon, J. G. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolff, Manfred E., Ed.; John Wiley and Sons: New York, 1996; Chapter 25, pp 3-58.
3. (c) Sastry, V. R. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolff, Manfred E., Ed.; John Wiley and Sons: New York, 1996; Chapter 26, pp 59-117.
4. (d) Latin, D. L. In Principles of Medicinal Chemistry, 4th ed.; Foye, W. O., Lemke, T. L., Williams, D. A., Eds.; Lippincott Williams & Wilkins, Philadelphia, PA, 1995; Chapter 17, pp 321-344.
5. Felder, C. C.; Bymaster, F. P.; Ward, J.; DeLapp, N. Therapeutic Opportunities of Muscarinic Receptors in the Central Nervous System. J. Med. Chem. 2000, 43, 4333-4353.
6. 1 Muscarinic Agonists. J. Med. Chem. 1998, 41, 379-392.
7. (a) Orlek, B. S.; Blaney, F. E.; Brown, F.; Clark, M. S. G.; Hadley, M. S.; Hatcher, J.; Riley, G. J.; Rosenberg, H. E.; Wadsworth, H. J.; Wyman, P. Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor. J. Med. Chem. 1991, 34, 2726-2735.
8. (b) Mitch, C. H.; Brown, T. J.; Bymaster, F. P.; Calligaro, D. O.; Dieckman, D.; Merrit, L.; Peters, S. C.; Quimby, S. J.; Shannon, H. E.; Shipley, L. A.; Ward, J. S.; Hansen, K.; Olesen, P. H.; Sauerberg, P.; Sheardown, M. J.; Swedberg, M. D. B.; Suzdak, P.; Greenwood, B. Muscarinic Analgesics with Potent and Selective Effects on the Gastrointestinal Tract: Potential Application for the Treatment of Irritable Bowel Syndrome. J. Med. Chem. 1997, 40, 538-546.
9. 1-Selective Muscarinic Agonist. J. Med. Chem. 1998, 41, 2524-2536.
10. (d) Greenlee, W.; Clader, J.; Asberom, T.; McCombie, S.; Ford, J.; Guzik, H.; Kozlowski, J.; Li, S.; Liu, C.; Lowe, D.; Vice, S.; Zhao, H.; Zhou, G.; Billard, W.; Binch, H.; Crosby, R.; Duffy, R.; Lachowicz, J.; Coffin, V.; Watkins, R.; Ruperto, V.; Strader, C.; Taylor, L.; Cox, K. Muscarinic Agonists and Antagonists in the Treatment of Alzheimer's Disease. Il Farmaco 2001, 56, 247-250.
11. (a) Sternbach, L. H.; Kaiser, S. Antispasmodics. I. Bicyclic Basic Alcohols. J. Am. Chem. Soc. 1952, 74, 2215-2218.
12. (b) Sternbach, L. H.; Kaiser, S. Antispasmodics. II. Esters of Basic Bicyclic Alcohols. J. Am. Chem. Soc. 1952, 74, 2219-2221.
13. Martell, M. J.; Soine, T. O. Esters of Bicyclic Amino Alcohols as Potential Anticholinergics III. Synthesis of Some Isomeric Hydroxy-1-azabicyclononanes and Certain of Their Esters. J. Pharm. Sci. 1963, 52, 331-336.
14. Yanina, A. D.; Rubtsov, M. V. Hofmann Cleavage of 1-Azabicyclo-(3,2,1)-octanes. II. Cleavage of 7-Methyl-1-azabicyclo-(3,2,1)-octane. J. Gen. Chem. USSR (English Transl.) 1960, 30, 548-554.
15. 4 Receptor Agonists and Gastric Motility Stimulants. J. Med. Chem. 1993, 36, 683-689.
16. Schaefer, J. P.; Bloomfield, J. J. The Dieckmann Condensation. Org. React. 1967, 15, 1-203.
17. (a) Yanina, A. D.; Rubtsov, M. V. Hofmann Degradation of 1-Azabicyclo-(3,2,1)-octane. J. Gen. Chem. USSR (English Transl.) 1959, 29, 485-491.
18. (b) Yanina, A. D.; Rubtsov, M. V. Hofmann Cleavage of 1-Azabicyclo[3,2,1]octanes. III. Hofmann Cleavage of the Quaternary Base 2-Methyl-1-Azabicyclo[3,2,1]octane. J. Gen. Chem. USSR (English Transl.) 1960, 30, 2527-2532.
19. (c) Mikhlina, E. E.; Rubtsov, M. V.; Vorob'eva, V. Ya. Synthesis of 2,3-Quinuclidinedicarboxylic Acid. J. Gen. Chem. USSR (English Transl.) 1960, 31, 3033-3036.
20. De Groot, S.; Strating, J. Resperine Analogues II. Recueil 1961, 80, 944-950.
21. Bolós, J.; Gubert, S.; Anglada, L.; Pérez, A.; Sacristán, A.; Oritz, J. A. Studies on the Hydrogenation of 6-(Hydroxymethyl)-pyridine-2-carboxylates and its Application to the Synthesis of 6-(Hydroxymethyl)piperidine-2-carboxylic Acid Derivatives. J. Heterocycl. Chem. 1994, 31, 1493-1496, and references therein.
22. Cohen, V. I.; Jin, B.; Reba, R. C. Facile and General Synthesis of 2-, 3-, or 4-[(Dialkylamino)alkyl]pyridines and -piperidines. Liebigs Ann. Chem. 1993, 809-810.
23. Mauleón, D.; Pujol, M. D.; Rosell, G. Synthesis and β-Adrenergic Antagonism of 2-(Aryloxy)-1-(2-piperidyl)ethanols. J. Med. Chem. 1988, 31, 2122-2126.
24. Bisel, P.; Gies, J. P.; Schlewer, G.; Wermuth, C. G. 6-(4-Phenylbenzyloxymethyl)guvacine. Synthesis, GABA Uptake Inhibitor and Muscarinic Properties. Bioorg. Med. Chem. Lett. 1990, 6, 3025-3028.
25. For related pyridine reductive methods, see: (a) Scopes, D. I. C.; Hayes, N. F.; Bays, D. E.; Belton, D.; Brain, J.; Brown, D. S.; Judd, D. B.; McElroy, A. D.; Meerholz, C. A.; Naylor, A.; Hayes, A. G.; Sheehan, M. J.; Birch, P. J.; Tyers, M. B. New κ-Receptor Agonists Based upon a 2-[(Alkylamino)methyl]piperidine Nucleus. J. Med. Chem. 1992, 35, 490-501.
26. 13NO from Dioscorine, and an Attempt at its Synthesis. J. Chem. Soc. 1963, 1841-1849.
27. 13C NMR Spectra of Saturated Heterocycles. 9. Piperidine and N-Methylpiperidine. J. Am. Chem. Soc. 1980, 102, 3698-3707.
28. Zacharie, B.; Moreau, N.; Dockendorff, C. A Mild Procedure for the Reduction of Pyridine N-Oxides to Piperidines Using Ammonium Formate. J. Org. Chem. 2001, 66, 5264-5265.
29. 18
30. Stothers, J. B. Carbon-13 NMR Spectroscopy; Academic Press: New York, 1972; pp 60-69.
31. Rubiralta, M.; Giralt, E.; Diez, A. In Piperieine. Structure, Preparation, Reaction and Synthetic Applications of Piperidine and its Derivatives; Elsevier: Amsterdam, 1991; Chapter 4, pp 128-130.
32. Birdsall, N. J. M. Muscarinic Acetylcholine Receptors. In The IUPHAR Compendium of Receptor Characterization and Classification; Girdlestone, D., Ed.; IUPHAR Media Ltd.: London, 2000; pp 54-63.
33. Boyer, J. L.; Romero, T.; Schachter, J. B.; Harden, T. K. Identification of Competitive Antagonists of the P2Y1-Receptor. Mol. Pharmacol. 1996, 50, 1323-1329.
34. 2 Subunit at Receptors and Effectors. J. Biol. Chem. 1998, 273, 34429-34436.
35. Eglen, R. M.; Choppin, A.; Dillon, M. P.; Hegde, S. Muscarinic Receptor Ligands and Their Therapeutic Potential. Curr. Opin. Chem. Biol. 1999, 3, 426-432.
36. (a) Farlow, F. R.; Evans, R. M. Pharmacological Treatment of Cognition in Alzheimer's Dementia. Neurology 1998, 51, 36S-44S
37. (b) Quirion, R.; Wilson, A.; Rowe, W.; Aubert, I.; Richard, J.; Doods, H. N.; Parent, A.; White, N.; Meaney, M. J. Facilitation of Acetylcholine Release and Cognitive Performance by an M(2)-Muscarinic Receptor Antagonist in Aged Memory-Impaired. J. Neurosci. 1995, 15, 1455-1462.
38. Rajeswaran, W. G.; Cao, Y.; Huang, X.-P.; Wroblewski, M. E.; Colclough, T.; Lee, S.; Liu, F.; Nagy, P. I.; Ellis, J.; Levine, B. A.; Nocka, K. H.; Messer, W. S., Jr. Design, Synthesis, and Biological Characterization of Bivalent 1-Methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole Derivatives as Selective Muscarinic Agonists. J. Med. Chem. 2001, 44, 4563-4576.
39. Christopoulos, A.; Grant, M. K. O.; Ayoubzadeh, N.; Kim, O. N.; Sauerberg, P.; Jeppesen, L.; El-Fakahany, E. E. Synthesis and Pharmacological Evaluation of Dimeric Muscarinic Acetylcholine Receptor Agonists. J. Pharmacol. Exp. Ther. 2001, 298, 1260-1268.
40. Portoghese, P. S. Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists. TIPS Rev. 1989, 10, 230-235.
41. Evans, T.; Smith, M. M.; Tanner, L. I.; Harden, T. K. Muscarinic Cholinergic Receptors of Two Cell Lines That Regulate Cyclic AMP Metabolism by Different Molecular Mechanisms. Mol. Pharmacol. 1984, 26, 395-404.